Marlene Plüß Kemal Mese Johannes T Kowallick Andreas Schuster Désirée Tampe Björn Tampe
10.3389/fimmu.2021.784145
Front Immunol
2022 Jan 18;12:784145.
chadox1 ncov-19 sars-cov-2 vaccination cytomegalovirus long covid viral reactivation
CC BY
https://pubmed.ncbi.nlm.nih.gov/35116025/
ChAdOx1 nCoV-19 / adverse effects Cytomegalovirus / drug effects Pericarditis / chemically induced SARS-CoV-2 / immunology Virus Activation / drug effects
ChAdOx1 nCoV-19 / adverse effects Cytomegalovirus / drug effects Pericarditis / chemically induced SARS-CoV-2 / immunology Virus Activation / drug effects Case Reports Aged Antiviral Agents / therapeutic use COVID-19 / prevention & control Cytomegalovirus / physiology Cytomegalovirus Infections / chemically induced Cytomegalovirus Infections / drug therapy Cytomegalovirus Infections / virology Female Humans Pericarditis / drug therapy Pericarditis / virology Treatment Outcome Valganciclovir / therapeutic use Viremia / chemically induced Viremia / drug therapy Viremia / virology Antiviral Agents ChAdOx1 nCoV-19 Valganciclovir
PMC8803643
35116025
Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2
2022